Sahsen Ventures

Archon Bio is a biotechnology company that specializes in engineering proteins to enhance therapeutic outcomes. It focuses on creating self-assembling protein antibody nanomaterials, aiming to improve immune modulation and super agonism of the TNF receptor superfamily. By increasing the size and valency of off-the-shelf antibodies, Archon seeks to induce stronger responses, thereby advancing regenerative medicine and cancer treatment.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Insamo operates a biotechnology platform designed to pioneer the discovery of membrane-permeable and orally available cyclic peptides, exhibiting antibody-like binding affinity. Its automated process combines molecular biology and parallel synthetic chemistry to rapidly identify preclinical candidates with favorable pharmacological properties, enabling healthcare professionals to enhance patient care by replacing injected or infused biologics with easily administered oral cyclic-peptide formulations.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Monod Bio is a life sciences company developing biosensors for detecting proteins, toxins, antibodies and other molecules. Its biosensor platform combines binding, transduction, and amplification in one step to detect a wide range of target molecules. The company leverages computational protein engineering to create modular bio-sensing nano switches that enable rapid, sensitive, and inexpensive analytical assays. Monod Bio was founded in 2021 and is headquartered in Seattle, Washington.

Founded in 2018, Terray Therapeutics is a biotechnology company based in Pasadena, California. It integrates experimentation and computation to enhance small molecule drug discovery, focusing on intractable diseases. The company's platform generates precise data through a rapid design-make-test-analyze cycle, enabling efficient exploration of chemical space.

HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

Inspire is a healthcare company that operates a patient engagement platform connecting patients and caregivers in a safe permission-based manner through a website and mobile app. The platform allows members to compare their health journeys and access a rich content environment, while enabling pharmaceutical organizations to integrate patient-connected longitudinal real-world data into research and product life cycles. The company focuses on supporting patients and advancing understanding of the patient journey to drive breakthroughs in pharmaceutical research. Inspire was founded in 2005 and is based in Arlington, Virginia.

Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.

Athira Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for brain disorders. Its lead product candidate, ATH-1017, aims to treat neurodegenerative diseases like Alzheimer's and Parkinson's by restoring neuronal health.

Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

TwinStrand Biosciences, established in 2015 and based in Bellevue, Washington, specializes in advancing DNA sequencing technology. The company's core innovation, Duplex Sequencing, enhances sequencing accuracy by over 10,000 times, enabling the detection of previously invisible mutations. This breakthrough technology has wide-ranging applications, including oncology, infectious disease diagnosis, organ transplant monitoring, genetic health, and forensics.

Agerpoint is a geospatial intelligence and data engineering company that builds a precision farming insights platform. It combines artificial intelligence, high‑performance computing, computer vision and advanced analytics to fuse data from mobile devices, ground vehicles, autonomous robots, drones, satellites, and human observations into a highly precise, quantifiable digital record of natural environments. The platform delivers actionable information on crop yields, disease detection, carbon sequestration, and biodiversity, and provides comprehensive GIS‑based asset inventories for growers, researchers, forestry managers, and government agencies. Founded in 2012 and headquartered in Research Triangle Park, North Carolina, Agerpoint’s mission is to improve quality of life and mitigate climate change by transforming how people understand and manage plants, crops, forests, and vegetation in built environments.

Andes Ag, Inc., founded in 2018 and headquartered in San Francisco, California, specializes in developing microbe-based seed technologies aimed at promoting sustainable agriculture. The company leverages beneficial microbes that have naturally co-evolved with plants over millennia. Through scientific research and advanced predictive software powered by artificial intelligence, Andes creates customized microbe-based formulations designed to enhance crop yields, accelerate growth, and enable cultivation in traditionally unsuitable lands. These solutions also aim to reduce the reliance on fertilizers and pesticides, helping farmers address the challenges posed by global climate change. Andes is positioned to contribute significantly to a new green revolution, fostering responsible and environmentally friendly agricultural practices.

NuProbe is a genomics and molecular diagnostics company that develops a platform of reagents and genetic toehold probes for noninvasive nucleic acid profiling. Their Sample‑In Answer‑Out solution integrates cell‑free DNA extraction, qPCR, sequencing and bioinformatics to detect mutations, CNVs, gene fusions and low‑frequency variants with high sensitivity. Founded in 2016, the company operates from Cambridge, Massachusetts and Shanghai, China, and focuses on early detection of cancer and infectious diseases for clinical and research use.

Variant Bio Inc. is a biotechnology company focused on developing therapeutics through the exploration of human genetic diversity. Founded in 2018 and headquartered in Seattle, Washington, the company seeks to identify individuals and populations exhibiting extreme outlier traits relevant to various medical conditions. By employing advanced sequencing technologies, statistical genetics, and machine learning, Variant Bio analyzes the genetic underpinnings of these traits to uncover new therapeutic targets. The company's mission is to enhance global health by addressing unmet medical needs, particularly in areas such as neurodegenerative, autoimmune, and cardiometabolic diseases.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. It specializes in the development of sustainable performance materials derived from microalgae and biobased oils. The company focuses on innovating materials at a molecular level, utilizing its expertise in molecular foundry, chemistry, material science, and fabrication technology. Checkerspot aims to expand the range of molecular building blocks available for high-performance materials, particularly in industrial applications such as polyurethanes and textile finishes. Through its pioneering approach, Checkerspot contributes to the advancement of sustainable materials in various industries.

Azitra is a clinical-stage dermatology company that leverages skin microbiome knowledge to develop novel treatments for adverse skin conditions and diseases.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Impact Vitals develops medical technologies that use advanced machine learning to monitor vital signs. Its solutions provide early warnings of potential issues, helping healthcare providers intervene earlier, improve patient outcomes, and reduce costs.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. It specializes in the development of sustainable performance materials derived from microalgae and biobased oils. The company focuses on innovating materials at a molecular level, utilizing its expertise in molecular foundry, chemistry, material science, and fabrication technology. Checkerspot aims to expand the range of molecular building blocks available for high-performance materials, particularly in industrial applications such as polyurethanes and textile finishes. Through its pioneering approach, Checkerspot contributes to the advancement of sustainable materials in various industries.

Ant Group Co., Ltd. is a leading provider of digital payment and financial services in China, known for its flagship product, Alipay, a widely used digital payments platform. Established in 2000 and headquartered in Hangzhou, the company offers a variety of financial solutions, including Yu'e Bao, an online cash management platform that invests users' funds in a money market fund; Huabei, a consumer credit service facilitating buy now, pay later options; and MYbank, an online bank focused on serving small businesses and entrepreneurs. Additionally, Ant Group operates Xiang Hu Bao, a mutual aid platform for health protection, and Zhima Credit, a credit assessment service for businesses. The company aims to foster digital transformation across the service industry, ensuring that consumers and small enterprises have equal access to inclusive and sustainable financial services. In July 2020, it rebranded from Ant Small and Micro Financial Services Group Co., Ltd. to Ant Group Co., Ltd.

Avail Medsystems, Inc. is a digital healthcare company based in Palo Alto, California, that specializes in developing a comprehensive hardware and software platform designed to connect healthcare professionals remotely. The company offers a fully integrated audio/visual system that facilitates real-time collaboration and procedural support, enabling practitioners to access clinical expertise and education without the constraints of physical location. By democratizing access to specialized knowledge and services, Avail Medsystems enhances the efficiency of healthcare delivery and promotes the adoption of innovative medical technologies. Founded in 2012 and previously known as Nurep, Inc., the company aims to improve patient care by bridging gaps between healthcare providers and medical technology experts.

Forterra is a non-profit organization that supports the Pacific Northwest and its wild mountains, rich ecosystems, farmland, small towns, and thriving cities.

Neoleukin Therapeutics is a biopharmaceutical company based in Seattle, Washington, founded in 2003. The company specializes in developing immunotherapies for cancer, inflammation, and autoimmune disorders using advanced protein design technology. Their lead product candidate, NL-201, is a de novo protein designed to mimic the therapeutic effects of cytokines interleukin (IL)-2/IL-15, targeting various types of cancer such as renal cell carcinoma and melanoma. Neoleukin Therapeutics leverages computational methods to create custom-designed proteins with enhanced pharmaceutical properties, inspired by natural protein complexes. The company emerged from the University of Washington Institute for Protein Design in January 2019 and was previously known as Aquinox Pharmaceuticals before changing its name in August 2019.

PVP Biologics, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapeutic products for celiac disease. Established in 2015, the company specializes in creating an oral enzyme designed to break down immuno-reactive components of gluten in the stomach. This approach aims to alleviate the painful symptoms and intestinal damage caused by accidental gluten ingestion in individuals with celiac disease. By advancing this product candidate, PVP Biologics seeks to significantly reduce the burden of living with this condition and improve the quality of life for those affected. As of early 2020, PVP Biologics operates as a subsidiary of Takeda Pharmaceutical Company Limited.

TwinStrand Biosciences, established in 2015 and based in Bellevue, Washington, specializes in advancing DNA sequencing technology. The company's core innovation, Duplex Sequencing, enhances sequencing accuracy by over 10,000 times, enabling the detection of previously invisible mutations. This breakthrough technology has wide-ranging applications, including oncology, infectious disease diagnosis, organ transplant monitoring, genetic health, and forensics.

SiDx is a health services provider based in Seattle, Washington, specializing in modernizing blood group testing. Founded in 2017, the company has developed a medical device that utilizes micro-sensors on a silicon chip, which are interrogated by laser to detect reactions to various compounds. This innovative diagnostic platform enables healthcare professionals to obtain test results during patient visits, significantly speeding up the care process and reducing associated costs. By enhancing the efficiency of blood testing, SiDx aims to improve patient care and streamline healthcare services.

Illumio, Inc. is a cybersecurity company based in Sunnyvale, California, founded in 2012. It specializes in providing cloud-based security solutions designed to protect organizations from cyber threats and breaches. The company's primary offering is the Adaptive Security Platform, which includes several tools such as Illumination for application traffic mapping, Enforcement for application nano-segmentation, and SecureConnect for data protection. Illumio's Zero Trust Segmentation Platform enhances security by visualizing traffic flows and automatically enforcing segmentation policies, minimizing lateral movement within multi-cloud and hybrid infrastructures. This approach safeguards critical resources and mitigates the risk of cyber attacks, thereby helping organizations maintain operational resilience. The company's clientele includes notable names such as Plantronics, Yahoo, and the Creative Artists Agency.

Rocket Pharmaceuticals is a biotechnology company focused on developing gene therapies for rare pediatric diseases. Its clinical-stage programs include treatments for Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.

Water1st International is a non-profit organization that provides and supports piped water systems and toilets projects for the world’s poorest communities that improve health, create opportunity, and break the cycle of extreme poverty.

MP Materials is a producer of rare earth materials in North America. It owns and operates the Mountain Pass mining and processing complex, including the mineral rights to Mountain Pass and surrounding areas, and holds related processing and development intellectual property. The company focuses on neodymium and praseodymium, key inputs for magnets used in electric vehicles, defense, wind turbines, drones and other technologies. Mountain Pass is the only scale rare earth mining and processing site in North America, with integrated operations that aim for cost efficiency and environmental standards. MP Materials is developing a rare earth metal, alloy and magnet manufacturing facility in Fort Worth, Texas, and operates in Materials and Magnetics segments. Founded in 2017 and headquartered in Las Vegas, it seeks to restore American leadership in this strategic industry.

Thorn is an organization focused on combating the sexual exploitation of children through technological innovation. Originally established as the Demi & Ashton Foundation, Thorn collaborates with various stakeholders, including the tech industry, government entities, and non-governmental organizations, to address and disrupt predatory behavior. By leveraging advanced technology, Thorn aims to rescue victims and enhance protections for vulnerable children, thereby creating a safer environment for youth.

PoliarisProject is a humanitarian organization that aims to combat human trafficking and modern-day slavery. The organization operates hotlines, policy advocacy programs, client services, advisory services, strategic initiatives, data analysis programs, and global programs to achieve its mission. PolarisProject is based in Washington, D.C.

Potlatch Fund is a non-profit organization dedicated to youth development, community building, language preservation and education, and native arts. They also provide training around financial management, board governance, strategic planning, media management, and nonprofit development for past grantees.

Amplio offers technology that overcomes barriers like low literacy, local languages, lack of electricity or internet, and traditional gender norms and biases that often limit access to information. With the battery-powered Amplio Talking Book, their partners can deliver hours of local language audio content.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to radically improve patients’ lives by decoding biology through the integration of biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates a large-scale drug discovery platform built around Recursion OS, an infrastructure layer and a Map of proprietary biological and chemical data, supported by software tools and machine learning to explore biology beyond human bias and identify new therapeutic opportunities. Its platform includes ReChem for selecting and designing compounds, ReScreen and ReScreenRun for planning and automating large-scale experiments, and ReRun, ReAnalyze, and RePredict for digital signatures, data analysis, and predictive modeling of drug relationships. Founded in 2013, the company is based in Salt Lake City, Utah.

98point6 Inc. is a healthcare technology company that offers on-demand virtual primary care services through its mobile application in the United States. Founded in 2015 and based in Seattle, Washington, the company provides a platform that enables board-certified physicians to deliver personalized consultations, diagnoses, and treatments for both acute and chronic illnesses. Utilizing a text-based interface, patients can receive care anytime and anywhere, allowing for efficient communication regarding their health concerns. The platform is designed to make healthcare more accessible and affordable, empowering physicians to focus more on patient care while leveraging technology to streamline processes such as prescribing medications and ordering lab tests.

Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Earth Economics is a nonpartisan, non-profit organization founded in 1998 that focuses on valuing nature and its benefits within decision making. It identifies and quantifies ecological and social benefits to ensure they are included in policy and business choices. The organization provides science-based economic analysis, policy recommendations, and tools to transform regional, national, and international economies. It offers asset accounting systems and training in natural capital and benefit-cost analysis, and serves government agencies, policymakers, businesses, non-profits, native communities, investors, multilateral organizations, and foundations.

Fred Hutchinson Cancer Research Center provides research services for the prevention, early detection, and treatment of cancer and other diseases in the United States and other countries. The research center is engaged in researches to prevent, detect, and treat cancer, HIV/AIDS, and other life-threatening diseases. Its activities in the areas of diseases and research cover fundamental research, prevention, early detection, treatment and cures, and survivorships. Researchers of Fred Hutchinson Cancer Research Center pioneered bone-marrow transplantation for leukemia and other blood diseases. This research has cured thousands of patients worldwide and has boosted survival rates for certain forms of leukemia from zero to 85 percent. Fred Hutchinson Cancer Research Center was incorporated in 1971 and is based in Seattle, Washington.

Owl Rock Capital Group, established in 2016, is a New York-based alternative asset manager specializing in credit investments. It caters to the financing needs of middle-market companies in the United States, providing tailored "one-stop" financing solutions across the capital structure. The company invests in senior secured or unsecured loans, subordinated loans, mezzanine loans, and to a lesser extent, equity-related securities and warrants. Owl Rock targets companies with annual EBITDA between $10 million and $250 million and revenue between $50 million and $2.5 billion. Its investment focus spans various sectors, including business services, consumer products, healthcare, industrials, software, and energy, among others. Owl Rock deploys capital through Owl Rock Capital Corporation, a business development company, and is managed by Owl Rock Capital Advisors, a SEC-registered investment adviser. The company's seasoned executives leverage their extensive experience to design and fund custom financing solutions, positioning Owl Rock as a preferred lending partner for middle-market companies and their sponsors.

Uterish operates as an online platform to connect activists, sell feminist apparel, publish an informative monthly newsletter, produce and curate opinionated blog posts, and support Planned Parenthood and the right to bodily autonomy.

GIRC&D is a community-based organization focused on the prudent use of natural and human resources. Originally sponsored by the U.S. Department of Agriculture and initially administered by the Natural Resources Conservation Service—a federal agency—we are now locally managed. The organization provides many avenues for worthy projects to succeed. Some projects that GIRC&D hosts are finite, but leave a lasting impact. Others become entities and nonprofit organizations on their own. Seven committees outreach to the community; one committee functions internally.

BROTMAN BATY INSTITUTE focuses on basic and applied research in genomics, bioinformatics, and data science to diagnose and cure disease. The Institute was founded in 2017 by philanthropic sponsors Jeff and Susan Brotman, and Dan and Pam Baty in collaboration with UW Medicine, The Fred Hutchinson Cancer Research Center, and Seattle Children’s. The Institute led by Dr. Jay Shendure was formed to accelerate both the basic sciences of precision medicine and the delivery of benefits to patients. The Institute organizes world-renowned investigators in genomics, bioinformatics and data science to share centralized platforms of advanced technologies and equipment in a uniquely collaborative manner. The Institute's aim is to develop insights and knowledge that will more precisely diagnose and treat people with cancer, rare childhood diseases, Alzheimer’s, and other conditions.

Founded in 2008 by Dr. Michela Gallagher, AgeneBio is a neuroscience pharmaceutical company dedicated to developing treatments for memory disorders. Its primary focus is on Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD), aiming to prevent neurodegeneration and preserve cognitive function.

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. Its leading products include envafolimab, an investigational PD-L1 single-domain antibody currently in pivotal trials for soft tissue sarcoma, and TRC102, a small molecule drug candidate in Phase II trials for lung cancer. Additionally, TRC253, designed for metastatic castration-resistant prostate cancer, is in Phase II development, while TJ004309, a CD73 antibody, is undergoing Phase I trials for solid tumors. TRACON operates a cost-efficient, contract research organization-independent product development platform and actively seeks partnerships with companies outside the U.S. to enhance regulatory and clinical development and commercialization efforts in the U.S. The company was founded in 2004 and was formerly known as Lexington Pharmaceuticals, Inc. before rebranding in 2005.

Roivant Sciences is a biopharmaceutical company dedicated to advancing the development of innovative late-stage drug candidates and enhancing healthcare delivery. The company aims to expedite the process of bringing new medicines to patients while reducing associated costs, thereby benefiting the healthcare system. Roivant achieves this by creating specialized entities known as "Vants," which are agile biotech and healthcare technology companies that leverage unique talent sourcing and incentive alignment strategies. In addition to its focus on biopharmaceuticals, Roivant incubates discovery-stage companies and health technology startups that complement its core business. Among its commercial-stage drug candidates is VTAMA, a treatment for plaque psoriasis in adults, along with several other candidates, including Batoclimab, IMVT-1402, Brepocitinib, and Namilumab, which are at various stages of development.

Adaptimmune Therapeutics is a biopharmaceutical company focused on developing novel cell therapies to treat solid tumors. It employs its proprietary SPEAR T-cell platform to identify cancer targets and generate therapeutic candidates for clinical trials.

Landesa is a charitable institution based in Seattle, Washington, founded in 1967. Initially known as the Center for Women's Land Rights, it rebranded in 2010 to reflect its broader mission. The organization focuses on helping marginalized populations secure legal rights to land, collaborating with governments, businesses, and local organizations to achieve this goal. By ensuring families have secure land rights, Landesa enables them to invest in their property, leading to improved agricultural productivity and sustainable livelihoods. This access to land rights contributes to enhanced nutrition, health, education, and overall resilience, ultimately fostering greater opportunities for future generations.

The mission of the University of Washington Institute for Protein Design is to design a new world of proteins to address 21st century challenges in medicine, energy and technology. The Institute for Protein Design was established in 2012, and is building on strengths within the University of Washington and Seattle more generally. Protein design requires high-level expertise and talent in computing and software, biochemistry, genome sciences, biological structure, pharmacology, immunology and other basic science disciplines, as well as clinical medicine. They are marshaling deep institutional strengths in our faculty, scientific staff, postdoctoral fellows and graduate students, their partners from collaborating institutions, innovator networks, and from the computer and biotechnology industries — bringing extraordinary expertise to bear on a singular focus to advance the potential of protein design. Over the past 16 years, UW researchers have made significant progress in protein design and protein structure prediction, developing the world leading Rosetta software. During this period, UW scientists have developed methods for designing proteins with a wide range of new functions, including catalysts for chemical reactions, HIV and RSV vaccine candidates, and flu virus inhibitors. The IPD integrates these strengths in protein design with Seattle-area expertise in biochemistry, engineering, computer science and medicine, and leverages the exceptional Seattle strength in the software industry.

Washington Environmental Council is a non-profit organization. To advocate for environmental progress and justice through actions that mobilize the public, elect champions for the environment. They builds power for the environmental movement through community organizing, mobilizing people to speak up on issues as well as attend hearings and other civic engagement opportunities. They also work to educate and train civic activists and support youth-led activists.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. Founded in 2010 and headquartered in Los Angeles, California, the company primarily focuses on the treatment of various forms of cancer, particularly through its lead product, NERLYNX, an oral formulation of neratinib designed for HER2-positive breast cancer patients. Additionally, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets the epidermal growth factor receptors HER1, HER2, and HER4. The company operates under a licensing agreement with Pfizer for the development and commercialization of its drug candidates, including oral and intravenous forms of neratinib, as well as PB357. With a commitment to enhancing treatment outcomes, Puma Biotechnology is focused on advancing its clinical programs and bringing effective therapies to market for cancer patients.

OCEAN FUTURES SOCIETY works to explore our global ocean, inspiring and educating people throughout the world to act responsibly for its protection, documenting the critical connection between humanity and nature, and celebrating the ocean's vital importance to the survival of all life on our planet.

Amara is an individual and family services organization that drives systemic change, promotes healing, racial, and LGBTQIA+ equity, by offering programs and services to families engaged in foster care, and to adoptees and families, post-adoption.

Plymouth Housing offers permanent homes and support services. They provide adults experiencing homelessness with opportunities to stabilise and improve their lives. They are preserving, developing, and operating safe, supportive housing.

Institute for Stem Cell and Regenerative Medicine (ISCRM) was founded in 2006 at the University of Washington by Tony Blau, Randy Moon, and Chuck Murry. The Institute is working to transform therapies for heart failure, neurodegenerative diseases including Parkinson’s and Alzheimer’s, muscular dystrophy, cancer, diabetes, hearing loss, and retinal, kidney, and liver diseases. Our scientists are conducting research using multiple approaches including pluripotent stem cell technology, gene therapy and precision medicine with the goal of developing novel therapies for diseases where there are few treatments at present.

Imagine a world where people are healthy. There would be less poverty and fewer orphans. There would be stronger economies. There would be hope.Seattle Biomedical Research Institute (Seattle BioMed) was founded at a time when infectious disease research in the U.S. was rare. Our founder had a vision to create a place where the brightest scientists could come together and generate new knowledge and develop innovative solutions to ultimately combat the world’s deadliest diseases. Today that vision is reality. 360 people strong, we're an internationally renowned, non-profit research Institute striving every day to eliminate the world's most devastating infectious disease.

R Baby is the first and only foundation focused on making sure every emergency room is prepared to give babies and children lifesaving care. The organization focuses on the delivery optimal pediatric emergency training, research, treatment, and equipment.

Ashesi University is a private, non-profit liberal arts institution located in Ghana, dedicated to educating the next generation of ethical and entrepreneurial leaders in Africa. Established in 2002 with an initial cohort of 30 students, the university has rapidly gained recognition for its innovative approach to higher education. Ashesi uniquely integrates a liberal arts core curriculum with specialized majors, including computer science, business administration, management information systems, and various engineering disciplines. By emphasizing critical thinking, social responsibility, and integrity, Ashesi aims to cultivate students who are equipped to drive positive change across the continent. The university's commitment to high-quality education not only seeks to elevate academic standards in Ghana but also aspires to contribute significantly to a broader renaissance in Africa.

Math for America is a charitable organization. They offer participation in a professional community, which is critical to sustaining teachers in their careers and attending, designing, and leading courses. It also developed a network of master teacher programs.

The Center for Constitutional Rights is dedicated to advancing and protecting the rights guaranteed by the United States Constitution and the Universal Declaration of Human Rights. Founded in 1966 by attorneys who represented civil rights movements in the South, CCR is a non-profit legal and educational organization committed to the creative use of law as a positive force for social change.

The Canada Green Building Council is involved in the design, construction, and operation of green buildings. They provide the products and services the building sector needs to construct and manage buildings that are easier on resources, healthier for people, and more cost-effective. Their government advocacy efforts help shape the government programs and policies that need to accelerate green buildings, lower carbon emissions, and create equitable communities.

Brady works across Congress, courts, and communities to end gun violence.

The Dian Fossey Gorilla Fund is a non-profit organization dedicated to gorilla conservation.

Pesticide Action Network North America is a pesticide and biotech corporation that creates a thriving food system. They grow food, placing the health and economic burdens of pesticide use on farmers, farmworkers, and rural communities. They link local and international consumers and labor into an international citizens action network.

Pomona College, founded in 1887 and located in Claremont, California, is a prestigious liberal arts institution known for its small class sizes and close student-faculty relationships. The college serves approximately 1,500 students, offering a diverse curriculum that spans the arts, humanities, social sciences, and natural sciences. With a student-faculty ratio of 8 to 1 and an average class size of 15, students benefit from personalized attention from accomplished faculty. Pomona is a founding member of The Claremont Colleges, providing students access to a wealth of resources typically associated with larger universities while maintaining the intimate atmosphere of a small college. The student body is characterized by its extraordinary ethnic and social diversity, enhancing the educational experience. Nestled within an hour's drive of various natural and cultural attractions, Pomona College offers unique opportunities for field study, community engagement, and internships. The college's endowment, amounting to $662 million, supports its mission and academic programs, solidifying its reputation as one of the nation’s premier liberal arts colleges.

Northwest Harvest distributes food to a network of more than 370 food banks, meal programs, and high-need schools throughout Washington State.

Queens College offers a rigorous education in the liberal arts and sciences under the guidance of a faculty dedicated to both teaching and research. Students graduate with the ability to think critically, address complex problems, explore various cultures, and use modern technologies and information resources.

As the political leader of the pro-choice movement, NARAL Pro-Choice America marshals its resources—the power of people, policy expertise, and political acumen—to make a difference in the lives of women and their families.With more than one million members and supporters, NARAL Pro-Choice America uses the political process to guarantee every woman the right to make personal decisions regarding the full range of reproductive choices, including preventing unintended pregnancy, bearing healthy children, and choosing legal abortion.We are working with the Obama administration and Congress to pursue commonsense solutions, like increasing access to family planning and sex education, and reversing President Bush's anti-choice legacy.

PACIFIC WILDLIFE PROJECT is a humane organization specializing in the rescue and care of wildlife. PACIFIC WILDLIFE PROJECT was Founded in 1985 with the humane goal of wildlife protection and preservation through education, community outreach, and rescue and medical treatment of all wild species.

Galapagos Conservancy is dedicated exclusively to the long-term protection of nature. Galapagos Conservancy is committed to strengthening local institutions and to creating local capacity to ensure the long-term protection of the archipelago.